Back to results
US 6,191,162 B1Granted
Method of reducing serum glucose levels
AssigneeMedical Research Institute
InventorsEdward A. Byrd, Rajiv Janjikhel
Life of this patent
Estimating the term…
Abstract
A controlled release formulation of lipoic acid is administered to a patient resulting in reduced serum glucose levels. The formulation comprises a pharmaceutically acceptable carrier and is designed to prevent degradation of the lipoic acid in the gastrointestinal tract and to release the lipoic acid in a controlled manner thereby obtaining a desired lipoic acid serum level over an extended period resulting in reduced serum glucose levels over that period.
Claims14
A method of reducing a patient's serum glucose level, comprising:
- administering to the patient a therapeutically effective amount of controlled release lipoic acid,
- wherein the lipoic acid is delivered to the patient's circulatory system at a continual rate over a period of four hours or more;
- wherein the lipoic acid is administered orally;
- wherein the lipoic acid is a racemic mixture administered in an amount in a range of from about 100 mg to about 1,000 mg;
- and
- wherein the lipoic acid composes a mixture of R-(+)-α-lipoic acid and S-(−)-α-lipoic acid, and ratio of R-(+)-α-lipoic acid to S-(−)-α-lipoic acid ranges from about 90:10 to about 10:90, respectively based on weight.
3 more elements
A controlled release oral dosage formulation, comprising:
- a therapeutically effective amount of lipoic acid;
- and a controlled release
- excipient formulation which releases the lipoic acid in a manner such that the lipoic acid is maintained in the patient's circulatory system at a substantially constant therapeutic level for a period of about four hours or more.
Dependencies are inferred from the claim text.